An overview of the new healthcare regulations
The Inflation Reduction Act’s key reforms
Get an overview of the law’s main changes to Medicare and other healthcare markets, and a timeline for implementation.
Read the articleOur experts’ analysis and guidance on the IRA
Milliman healthcare leaders discuss the law’s provisions and their potential impact on payers, drugmakers, and other stakeholders.
Watch the webinarLessons from the first drugs chosen for Medicare price negotiation
The Inflation Reduction Act requires drug manufacturers to negotiate prices with the federal government, a change with wide-ranging implications for the pharmaceutical industry and healthcare payers.
View the paper
Insight
How should pharmaceutical manufacturers strategize, given the new IRA provisions?
As drugmakers adapt to insulin copay caps, rebate penalties, and more regulatory provisions that impact pricing, we lay out key items to watch and offer preparation strategies.
Read the articleHow the IRA affects Medicare Part D risk and claim costs
Milliman’s actuaries analyzed how the new Medicare Part D benefit redesign will affect plan liability and risk for health plan sponsors and present risk-mitigation strategies.
See our findingsRecommended for you
Milliman MACVAT (Medicare Advantage Competitive Value Added Tool)
Evaluate relative values of Medicare Advantage program plans using a comprehensive, Excel-based tool.
Life sciences
Our solutions are tailored to your needs, whether you’re focused on small molecule pharma, gene and cell therapies, rare disease, biosimilars, or medical devices.